VTI1B Antibody

What is VTI1B and why is it a target of interest for antibody-based detection?

VTI1B (vesicle transport through interaction with t-SNAREs homolog 1B) is a 27 kDa SNARE protein that functions as a critical mediator of vesicle trafficking and membrane fusion events. It contains a Qb SNARE motif that enables the formation of complexes with other SNARE proteins such as syntaxin 7, syntaxin 8, and endobrevin/VAMP-8 .

VTI1B is primarily localized to the Golgi complex, endosomes (particularly late endosomes), lysosomes, and areas surrounding the microtubule-organizing center (MTOC) . Its involvement in multiple cellular processes including autophagy, endosomal-lysosomal trafficking, and secretory pathways makes it an important target for researchers studying vesicle transport, protein sorting, and membrane dynamics .

How do polyclonal and monoclonal VTI1B antibodies differ in research applications?

Polyclonal VTI1B Antibodies:

• Recognize multiple epitopes on the VTI1B protein, potentially providing stronger signals in applications where the protein might be partially denatured or fixed

• Examples include rabbit polyclonal antibodies like CAB7062 that target recombinant fusion proteins containing amino acids 1-210 of human VTI1B

• Generally exhibit broad species cross-reactivity (human, mouse, rat)

• Particularly useful for applications requiring high sensitivity such as detection of endogenous protein levels

Monoclonal VTI1B Antibodies:

• Target a single epitope, providing greater specificity but potentially less signal amplification

• Examples include rabbit monoclonal antibody EPR15506(B) (ab184170) and mouse monoclonal clone 7/Vti1b

• Provide consistent lot-to-lot reproducibility, advantageous for longitudinal studies

• Particularly valuable for distinguishing between closely related proteins (e.g., VTI1B vs. VTI1A)

Selection should be based on the specific research requirements, with polyclonals offering higher sensitivity for detection of low abundance targets, and monoclonals providing superior specificity for discriminating between homologous proteins .

What are the optimal conditions for using VTI1B antibodies in immunofluorescence studies of vesicular trafficking?

For optimal immunofluorescence detection of VTI1B in vesicular trafficking studies:

Sample Preparation Protocol:

• Fix cells with 4% paraformaldehyde for 10 minutes at room temperature

• Block and permeabilize simultaneously using 5% donkey serum with 0.3% Triton X-100 in PBS for 20 minutes at room temperature

• Incubate with primary VTI1B antibody (diluted in 1% BSA, 0.3% Triton X-100 in PBS) overnight at 4°C

• Wash thoroughly with PBS and incubate with appropriate fluorescently-labeled secondary antibodies for 30 minutes at room temperature

Antibody Selection and Dilution:

• For detection of endogenous VTI1B: Use rabbit polyclonal antibodies at 1:50-1:200 dilution

• For co-localization studies: Consider rabbit monoclonal antibodies like EPR15506(B) which have been validated for ICC/IF applications

Co-staining Markers:
For meaningful vesicular trafficking analysis, co-stain with compartment-specific markers:

• Rab6 for Golgi apparatus

• Rab7 for late endosomes

• Rab11 for recycling endosomes

• LAMP1 for lysosomes

This approach allows precise localization of VTI1B in different vesicular compartments and facilitates the analysis of its dynamics during cellular processes such as BCR activation or antigen processing .

How should researchers design experiments to investigate VTI1B interactions with other SNARE proteins using antibody-based approaches?

Experimental Design for SNARE Interaction Studies:

• Co-immunoprecipitation (Co-IP):

  • Use 0.5-4.0 μg of VTI1B antibody per 1.0-3.0 mg of total protein lysate

  • Include appropriate controls: IgG isotype control, reverse Co-IP with antibodies against potential interacting partners

  • Lyse cells in buffers containing mild detergents (e.g., 1% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions

  • Validate interactions by immunoblotting for known partners (syntaxin 7, syntaxin 8, endobrevin/VAMP-8)

• Proximity Ligation Assay (PLA):

  • Combine rabbit anti-VTI1B with mouse antibodies against potential SNARE partners

  • Use species-specific PLA probes to visualize interactions within intact cells

  • Quantify interaction signals relative to appropriate negative controls

• FRET/FLIM Analysis:

  • Express fluorescently tagged VTI1B and candidate interacting SNARE proteins

  • Measure FRET efficiency as an indicator of molecular proximity

  • Compare resting cells with stimulated conditions (e.g., BCR activation) to assess dynamic regulation of interactions

• Validation in Knockout/Knockdown Systems:

  • Utilize available Vti1b-deficient mouse models or cells for antibody specificity validation

  • Implement siRNA knockdown of VTI1B to assess effects on SNARE complex formation

  • Complement with reconstitution experiments using wild-type or mutant VTI1B constructs

This multi-faceted approach provides comprehensive characterization of VTI1B interactions with other SNARE proteins and helps elucidate its functional role in specific vesicular trafficking pathways.

How should researchers interpret changes in VTI1B localization following B cell receptor (BCR) activation?

Interpreting changes in VTI1B localization following BCR activation requires careful analysis of spatiotemporal dynamics:

Key Localization Patterns to Monitor:

• Resting B Cells:

  • VTI1B primarily localizes to the Golgi complex, MTOC region, and Rab7-positive lysosomal vesicles in the cell periphery

  • Baseline distribution serves as the reference point for activation-induced changes

• Early BCR Activation (Soluble Antigen):

  • VTI1B shows partial localization to internalized antigen vesicles, particularly in the cell periphery

  • Quantify co-localization with internalized BCR/antigen complexes using Pearson's correlation coefficient or Mander's overlap coefficient

• Immunological Synapse Formation (Surface-bound Antigen):

  • VTI1B polarizes to the immunological synapse

  • Co-localizes with the Golgi complex and with lysosomes at actin foci

  • Compare kinetics of VTI1B recruitment relative to other markers (BCR, actin, Golgi)

Analytical Framework:

• Perform time-course experiments (0-60 minutes post-activation)

• Quantify the percentage of cells showing VTI1B redistribution at each timepoint

• Measure the relative enrichment of VTI1B at various subcellular compartments

• Compare wild-type cells with Vti1b-deficient or Vti1b-depleted cells to establish specificity

Functional Interpretation:
Despite striking redistribution of VTI1B following BCR activation, functional studies in Vti1b-deficient primary mouse B cells revealed no defects in BCR signaling, immunological synapse formation, or antigen processing/presentation. This suggests potential compensatory mechanisms, possibly involving the homolog Vti1a or other SNARE proteins . When interpreting localization data, researchers should consider the possibility of functional redundancy in the SNARE system.

What controls should be implemented when validating VTI1B antibody specificity in knockout/knockdown systems?

Rigorous validation of VTI1B antibodies requires comprehensive controls in knockout/knockdown systems:

Essential Validation Controls:

• Genetic Controls:

  • Vti1b knockout mouse models: Use tissues/cells from Vti1b-null mice alongside wild-type and heterozygous controls to confirm antibody specificity

  • siRNA/shRNA knockdown: Compare cells treated with VTI1B-targeted versus non-targeting control siRNAs

  • CRISPR/Cas9 knockout cell lines: Use validated VTI1B knockout cell lines (e.g., HeLa VTI1B knockout)

• Expression Controls:

  • Overexpression systems: Test antibody reactivity in cells overexpressing tagged VTI1B constructs

  • Rescue experiments: Reintroduce wild-type VTI1B in knockout cells to restore antibody signal

• Technical Controls:

  • Loading controls: Include housekeeping proteins (GAPDH, β-actin) to normalize for protein loading

  • Multiple detection methods: Validate specificity across different applications (WB, IHC, IF)

  • Competition assays: Pre-incubate antibody with recombinant VTI1B protein to block specific binding

• Cross-reactivity Assessment:

  • Test reactivity against the homologous protein VTI1A (33% identical to VTI1B)

  • Examine potential cross-reactivity with other SNARE family members

  • Use tissues/cells from double knockout (Vti1a/Vti1b) models for comprehensive validation

Validation Data Analysis:

• Complete absence of signal in knockout samples confirms high specificity

• Reduced signal proportional to knockdown efficiency indicates antibody specificity

• Persistent signal in knockout samples suggests cross-reactivity with related proteins

• Unexpected molecular weight bands may indicate non-specific binding or protein modifications

Published studies have successfully demonstrated the specificity of various VTI1B antibodies using these validation approaches, with knockout samples showing complete loss of signal at the expected molecular weight (27-29 kDa) .

How can researchers effectively use VTI1B antibodies to investigate its role in autophagy and autolysosomal pathways?

Investigating VTI1B's role in autophagy requires sophisticated antibody-based approaches:

Methodological Framework:

• Co-localization Analysis:

  • Monitor VTI1B association with autophagy markers during autophagy induction:

    • LC3-II for autophagosomes

    • p62/SQSTM1 for autophagy substrates

    • LAMP1/2 for lysosomes/autolysosomes

  • Quantify co-localization under basal, starvation-induced, and drug-modulated (rapamycin, bafilomycin A1) autophagy conditions

  • Use super-resolution microscopy (STED, STORM) to precisely localize VTI1B at autophagosome-lysosome contact sites

• Autophagic Flux Assessment:

  • Compare LC3-II turnover between control and VTI1B-depleted cells using VTI1B antibodies to confirm knockdown efficiency

  • Monitor p62 degradation kinetics in the presence/absence of VTI1B

  • Employ tandem fluorescent-tagged LC3 (mRFP-GFP-LC3) to assess autolysosome formation in VTI1B-manipulated cells

• SNARE Complex Analysis:

  • Use VTI1B antibodies in sequential immunoprecipitation to isolate specific SNARE complexes involved in autophagosome-lysosome fusion

  • Perform proximity labeling (BioID, APEX) with VTI1B as bait to identify novel interactors during autophagy

  • Analyze the composition of SNARE complexes containing VTI1B under different autophagy conditions

• Ultrastructural Analysis:

  • Combine VTI1B immunogold labeling with electron microscopy to precisely localize the protein at autophagosomal membranes

  • Quantify autophagic vacuoles in hepatocytes from wild-type versus Vti1b-deficient mice, which have been reported to accumulate in the latter

Interpretative Framework:
VTI1B forms complexes with syntaxin 7, syntaxin 8, and VAMP7 to mediate fusion between recycling endosomes and autophagosomes . It also participates in fusion events involving GAS-containing autophagosome-like vacuoles (GcAVs) and recycling endosomes through complexes with syntaxins and VAMP3 . Researchers should interpret their findings in the context of these established functions while remaining open to cell type-specific roles of VTI1B in autophagy.

What methodological approaches can researchers use to study the interplay between VTI1B and TRPV1 in inflammatory pain models?

Investigating the VTI1B-TRPV1 interaction in inflammatory pain requires specialized methodological approaches:

Experimental Strategies:

• Biochemical Interaction Analysis:

  • Co-immunoprecipitation: Use anti-VTI1B antibodies to pull down protein complexes from dorsal root ganglia (DRG) lysates under normal and inflammatory conditions

  • Proximity labeling: Apply BioID or APEX2 fused to VTI1B to identify its interaction network in sensory neurons

  • Validate interactions with reciprocal co-IP using TRPV1 antibodies

  • Compare interaction profiles between naive and inflammatory pain models

• Localization Studies in Sensory Neurons:

  • Immunofluorescence co-localization of VTI1B and TRPV1 in DRG neurons under basal and inflammatory conditions

  • Live-cell imaging with fluorescently tagged VTI1B to track its dynamics during TRPV1 activation

  • Super-resolution microscopy to precisely define spatial relationships between these proteins at the plasma membrane and in vesicular compartments

• Functional Analysis:

  • Patch-clamp electrophysiology in sensory neurons from wild-type and Vti1b-deficient mice to assess TRPV1 sensitization

  • Calcium imaging to measure TRPV1 activity following manipulation of VTI1B expression

  • Behavioral testing (thermal and mechanical hyperalgesia) in animal models with neuron-specific VTI1B knockdown/knockout

• Trafficking Studies:

  • Surface biotinylation assays to measure TRPV1 membrane insertion in the presence/absence of VTI1B

  • TIRF microscopy to visualize real-time changes in membrane-proximal TRPV1-containing vesicles

  • Quantitative immunocytochemistry with VTI1B antibodies to assess subcellular distribution changes during inflammation

Analytical Framework:
Research has demonstrated that VTI1B promotes TRPV1 sensitization during inflammatory pain, though the exact mechanism remains under investigation . When designing experiments, researchers should consider multiple potential mechanisms:

• Direct interaction affecting TRPV1 channel properties

• Regulation of TRPV1 trafficking to the plasma membrane

• Modulation of TRPV1 internalization or recycling

• Effects on TRPV1 association with other regulatory proteins

These methodological approaches, combined with appropriate controls and quantitative analysis, will help elucidate the specific role of VTI1B in TRPV1-mediated pain sensitization.

What are the common technical challenges when using VTI1B antibodies in immunohistochemistry, and how can they be addressed?

Common Challenges and Solutions:

• Weak or Absent Signal:

  • Cause: Insufficient antigen retrieval or low VTI1B expression

  • Solution: Optimize antigen retrieval by testing multiple methods:

    • Heat-induced epitope retrieval with 10 mM PBS buffer (pH 7.2)

    • TE buffer (pH 9.0) for improved results with some antibodies

    • Citrate buffer (pH 6.0) as an alternative retrieval method

  • Increase antibody concentration (1:50 dilution for challenging samples)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal amplification systems (e.g., tyramide signal amplification)

• High Background:

  • Cause: Non-specific binding or excessive antibody concentration

  • Solution: Optimize blocking (5-10% normal serum from secondary antibody host species)

  • Increase washing steps (duration and number)

  • Titrate antibody concentration (test 1:50 to 1:500 dilutions)

  • Pre-absorb antibody with blocking peptide if available

• Cross-reactivity with VTI1A:

  • Cause: Homology between VTI1B and VTI1A (33% sequence identity)

  • Solution: Use monoclonal antibodies specifically validated against VTI1A/B cross-reactivity

  • Include VTI1B knockout tissue as negative control

  • Perform parallel staining with VTI1A-specific antibodies for comparison

• Variable Results Across Tissue Types:

  • Cause: Tissue-specific differences in VTI1B expression or accessibility

  • Solution: Optimize fixation protocols for each tissue type

  • Adjust antigen retrieval time based on tissue density

  • Validate antibody performance in each target tissue (reported success in human liver cancer and malignant melanoma tissues)

Recommended Protocol Modifications:
For challenging tissues, implement a sequential detection approach:

• Primary VTI1B antibody (1:50 dilution, overnight at 4°C)

• Biotinylated secondary antibody (1 hour at room temperature)

• Streptavidin-HRP conjugate (30 minutes at room temperature)

• Tyramide signal amplification

• Counterstain with appropriate nuclear dye

These modifications have been successfully employed to detect VTI1B in various tissue types, including liver cancer and esophageal cancer specimens .

How can researchers address inconsistent results when studying VTI1B knockout phenotypes across different cell types?

Addressing Phenotypic Variability in VTI1B Knockout Studies:

• Consider Compensatory Mechanisms:

  • Observation: Vti1b knockout mice show surprisingly mild phenotypes despite VTI1B's role in crucial cellular processes

  • Approach: Analyze expression levels of VTI1A and other functionally related SNAREs in knockout models

  • Generate and characterize double knockout models (e.g., Vti1a/Vti1b DKO) to overcome redundancy

  • Perform acute depletion (inducible knockout or rapid degradation) to bypass long-term compensation

• Cell Type-Specific Effects:

  • Observation: Phenotypes vary across different cell types (e.g., more pronounced in hepatocytes than B cells)

  • Approach: Characterize VTI1B expression levels and subcellular distribution across cell types using validated antibodies

  • Implement cell type-specific knockout approaches using Cre-loxP systems

  • Analyze tissue-specific SNARE complex compositions to identify cell type-specific partners

• Analytical Considerations:

  • Observation: Subtle phenotypes may be missed without appropriate assays

  • Approach: Employ multiple functional readouts (kinetic assays, stress conditions)

  • Quantify endosomal/lysosomal morphology using electron microscopy

  • Measure degradation kinetics of multiple endocytic cargoes

  • Assess autophagic flux under both basal and stressed conditions

• Experimental Design Refinements:

  • Observation: Different laboratories report varying phenotype severity

  • Approach: Standardize experimental conditions (cell culture media, passage number, confluency)

  • Include heterozygous controls to detect gene dosage effects

  • Perform rescue experiments with multiple VTI1B variants to identify critical domains

  • Consider environment and genetic background effects in animal models

Integrative Analysis Framework:
Published studies have revealed that while Vti1b-deficient mice lack serious defects, some exhibit reduced size compared to littermates. Lysosomal degradation of endocytosed proteins may be slightly delayed, and multivesicular bodies and autophagic vacuoles can accumulate in hepatocytes of smaller Vti1b-knockout mice . These findings indicate that phenotypic manifestations may be subtle and context-dependent, requiring comprehensive analytical approaches to fully characterize the functional consequences of VTI1B loss.

How can researchers leverage VTI1B antibodies to explore its potential role in neurodegenerative disorders and protein trafficking abnormalities?

Methodological Approaches for Neurodegenerative Disease Research:

• Tissue Analysis from Disease Models:

  • Application: Utilize VTI1B antibodies for immunohistochemical analysis of brain tissues from neurodegenerative disease models

  • Approach: Compare VTI1B expression patterns and levels between control and disease tissues

  • Investigate co-localization with disease-specific protein aggregates (Aβ, tau, α-synuclein)

  • Analyze relationships with autophagy markers, as defective autophagy is implicated in neurodegeneration

• Trafficking Dynamics of Disease-Associated Proteins:

  • Application: Study the role of VTI1B in the trafficking of proteins implicated in neurodegeneration

  • Approach: Track trafficking of fluorescently tagged disease proteins in the presence/absence of VTI1B

  • Use live-cell imaging to measure vesicular transport kinetics before and after VTI1B manipulation

  • Implement proximity labeling approaches to identify disease-specific VTI1B interactors

• Autophagy-Lysosome Pathway Analysis:

  • Application: Examine VTI1B's contribution to clearance of protein aggregates via autophagy

  • Approach: Quantify autophagic flux in neuronal models with VTI1B knockdown/knockout

  • Measure degradation rates of disease-associated proteins

  • Assess effects of VTI1B modulation on neuronal survival under proteotoxic stress

  • Utilize VTI1B antibodies to monitor its recruitment to autophagosomes containing pathological aggregates

• Therapeutic Modulation Strategies:

  • Application: Evaluate VTI1B as a potential therapeutic target for enhancing protein clearance

  • Approach: Screen for compounds that modulate VTI1B expression or function

  • Validate hits using VTI1B antibodies to confirm target engagement

  • Assess downstream effects on protein trafficking and degradation pathways

Research Framework:
VTI1B's involvement in intracellular transport pathways makes it a relevant target for investigations into diseases related to protein trafficking abnormalities, such as neurodegenerative disorders . Recent evidence suggests that VTI1B, through its role in autophagosomal maturation and lysosomal fusion, may contribute to cellular homeostasis mechanisms that are compromised in neurodegeneration . Researchers should design experiments that address both acute trafficking defects and chronic consequences of VTI1B dysfunction in neuronal systems.

What are the methodological considerations for investigating VTI1B's role in immune cell function beyond B cells?

Comprehensive Methodological Framework:

• Comparative Expression Analysis Across Immune Cell Types:

  • Application: Characterize VTI1B expression patterns across immune cell lineages

  • Approach: Use validated VTI1B antibodies for Western blot and immunofluorescence analysis of:

    • T cell subsets (CD4+, CD8+, Tregs)

    • Macrophages and dendritic cells

    • NK cells and innate lymphoid cells

  • Implement flow cytometry with intracellular VTI1B staining to quantify expression at the single-cell level

  • Correlate expression with activation status and functional capabilities

• Functional Assays in Specific Immune Cell Types:

  • Application: Define VTI1B's role in cell type-specific immune functions

  • Approach: For cytotoxic T lymphocytes:

    • Assess lytic granule exocytosis (a known VTI1B-dependent process)

    • Measure target cell killing efficiency after VTI1B knockdown

  • For macrophages:

    • Evaluate cytokine secretion and trafficking

    • Analyze phagocytosis and phagosome-lysosome fusion

  • For dendritic cells:

    • Investigate antigen processing and presentation pathways

    • Assess MHC class II trafficking (relevant given VTI1B's interaction with invariant chain)

• Vesicular Trafficking in Immune Synapse Formation:

  • Application: Examine VTI1B's contribution to immune synapse architecture

  • Approach: Use high-resolution imaging to track VTI1B dynamics during immune synapse formation

  • Compare polarization patterns between B cells, T cells, and NK cells

  • Assess recruitment kinetics in relation to functional outcomes

  • Implement optogenetic approaches to manipulate VTI1B localization during synapse formation

• Single-Cell Multi-omics Integration:

  • Application: Correlate VTI1B expression with functional immune cell states

  • Approach: Combine single-cell transcriptomics, proteomics, and functional assays

  • Implement spatial transcriptomics to analyze VTI1B expression patterns in tissue microenvironments

  • Correlate findings with immunohistochemical detection using VTI1B antibodies

Analytical Considerations:
Studies have revealed diverse roles for VTI1B across immune cell types, including participation in lytic granule exocytosis in cytotoxic T cells , regulation of post-Golgi trafficking of cytokines in macrophages , and involvement in antigen processing via interaction with the invariant chain of MHCII . These findings suggest that VTI1B functions in both shared and specialized trafficking pathways across immune cell lineages. Researchers should design comparative studies that can distinguish conserved from cell type-specific functions while accounting for potential redundancy with VTI1A or other SNAREs.

VTI1B Antibody Selection Guide for Different Applications

Comparative Analysis of VTI1B Expression and Localization Across Cell Types

VTI1B Knockout/Knockdown Phenotypes and Their Implications for Antibody-Based Studies